We propose the potential of CEP-1347 as an effective option for UM; it is a novel MDM4 inhibitor that has been shown to down-regulate MDM4 and activate p53 in retinoblastoma, glioblastoma, and malignant meningioma cells [16,17,18]. This evidence concerns the gene TP53 and retinoblastoma.